Company intelligence / Profile preview

Pledge Therapeutics

Canton, Massachusetts, United Statespledge-tx.com ↗

Ownership: Private
Employees: ~16
Development stage: Preclinical

Overview

Pledge Therapeutics uses advanced structure-based drug discovery to develop first-in-class small molecule therapeutics against challenging disease targets. Their initial focus includes antivirals for BK and JC polyomavirus infections in transplant patients. The company has announced preclinical progress on its HHLA2 and IL18BP programs as well as the development of a first antiviral targeting BK virus. No clinical results have been published yet; all lead assets are preclinical.

Therapeutic areas: OtherOncologyInfectious Diseases
Modalities: small molecules
Industry: Biotech

Beyond the preview

Go deeper on Pledge Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pledge Therapeutics.

Explore the full profile